EBIT: Income before interest and taxes.
Neumora Therapeutics, Inc. (NMRA) had EBIT of $-57.70M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-56.76M |
|
-- |
|
-- |
|
$57.70M |
|
$-57.70M |
|
$0.94M |
|
$-56.76M |
|
$-56.76M |
|
$-56.76M |
|
$-56.76M |
|
$-56.76M |
|
$-56.76M |
|
|
EBIT |
$-57.70M |
$-58.29M |
|
161.84M |
|
161.84M |
|
$-0.35 |
|
$-0.35 |
|
| Balance Sheet Financials | |
$177.08M |
|
$0.08M |
|
$0.75M |
|
$177.83M |
|
$25.84M |
|
$19.56M |
|
$19.83M |
|
$45.67M |
|
$132.16M |
|
$132.16M |
|
$132.16M |
|
161.95M |
|
| Cash Flow Statement Financials | |
$-158.49M |
|
$125.87M |
|
$18.32M |
|
$143.36M |
|
$129.07M |
|
$-14.29M |
|
$22.47M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.85 |
|
-- |
|
-- |
|
0.13 |
|
0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-158.33M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-42.94% |
|
-42.94% |
|
-31.91% |
|
-37.41% |
|
$0.82 |
|
$-0.98 |
|
$-0.98 |
|